Performance evaluation of SARS-CoV-2 rapid diagnostic tests in Nigeria : a cross-sectional study

dc.contributor.authorOmonkhua, Akhere A.
dc.contributor.authorFaneye, Adedayo
dc.contributor.authorAkinwande, Kazeem S.
dc.contributor.authorEvaezi, Okpokoro
dc.contributor.authorShehu, Nathan Y.
dc.contributor.authorOnayade, Adedeji
dc.contributor.authorOchu, Chinwe Lucia
dc.contributor.authorPopoola, Mustapha
dc.contributor.authorEmmanuel, Nnadi
dc.contributor.authorOjo, Temitope
dc.contributor.authorOhonsi, Cornelius
dc.contributor.authorAbubakar, Abdullahi
dc.contributor.authorOdeh, Elizabeth
dc.contributor.authorAkinduti, Paul
dc.contributor.authorFolarin, Onikepe
dc.contributor.authorBimba, John Samson
dc.contributor.authorIgumbor, Ehimario
dc.contributor.authorElimian, Kelly
dc.contributor.authorEdem, Victory Fabian
dc.contributor.authorLuka, Pam D.
dc.contributor.authorOlusola, Tunde
dc.contributor.authorNtoimo, Loretta
dc.contributor.authorOlugbile, Michael
dc.contributor.authorOpayele, Adewale Victor
dc.contributor.authorKida, Ibrahim
dc.contributor.authorDavid, Shwe
dc.contributor.authorOnyeaghala, Augustine
dc.contributor.authorIgbarumah, Isaac
dc.contributor.authorMaduka , Omosivie
dc.contributor.authorMahmoud, Magaji A.
dc.contributor.authorEl-Fulatty, Abdul Rahman
dc.contributor.authorOlaleye, David O.
dc.contributor.authorSimon, Omale
dc.contributor.authorOsaigbovo, Iriagbonse Iyabo
dc.contributor.authorObaseki, Darlington Ewaen
dc.contributor.authorTolulupe, Afolaranmi
dc.contributor.authorHappi, Christian
dc.contributor.authorJibrin, Yusuf Bara
dc.contributor.authorOkonofua, Friday
dc.contributor.authorEliya, Timan
dc.contributor.authorSimji, Gomerep
dc.contributor.authorIzang, Joy Abi
dc.contributor.authorAmeh, Emmanuel
dc.contributor.authorMaigari, Ibrahim Mahmood
dc.contributor.authorAlhaji, Sulaiman
dc.contributor.authorAdetifa , Ifedayo
dc.contributor.authorSalako, Babatunde
dc.contributor.authorBogoro, Suleiman
dc.contributor.authorIhekweazu, Chikwe
dc.contributor.authorOdaibo, Georgina N.
dc.contributor.authorCOVID-19 RDT Validation in Nigeria (CORVAN) study group
dc.date.accessioned2025-06-11T05:46:31Z
dc.date.available2025-06-11T05:46:31Z
dc.date.issued2024-07-15
dc.descriptionDATA AVAILABILITY STATEMENT : The data was entered into the research electronic data capture (REDCap) tool and are all available within the paper.
dc.description.abstractThe COVID-19 pandemic challenged health systems globally. Reverse transcription polymerase chain reaction (RT-PCR) is the gold standard for detecting the presence of SARS-CoV-2 in clinical samples. Rapid diagnostic test (RDT) kits for COVID-19 have been widely used in Nigeria. This has greatly improved test turnover rates and significantly decreased the high technical demands of RT-PCR. However, there is currently no nationally representative evaluation of the performance characteristics and reliability of these kits. This study assessed the sensitivity, specificity, and predictive values of ten RDT kits used for COVID-19 testing in Nigeria. This large multi-centred cross-sectional study was conducted across the 6 geo-political zones of Nigeria over four months. Ten antigen (Ag) and antibody (Ab) RDT kits were evaluated, and the results were compared with RT-PCR. One thousand, three hundred and ten (1,310) consenting adults comprising 767 (58.5%) males and 543 (41.5%) females participated in the study. The highest proportion, 757 (57.7%), were in the 20–39 years’ age group. In terms of diagnostic performance, Lumira Dx (61.4, 95% CI: 52.4–69.9) had the highest sensitivity while MP SARS and Panbio (98.5, 95% CI: 96.6–99.5) had the highest specificity. For predictive values, Panbio (90.7, 95% CI: 79.7–96.9) and Lumira Dx (81.2, 95% CI: 75.9–85.7) recorded the highest PPV and NPV respectively. Ag-RDTs had better performance characteristics compared with Ab-RDTs; however, the sensitivities of all RDTs in this study were generally low. The relatively high specificity of Ag-RDTs makes them useful for the diagnosis of infection in COVID-19 suspected cases where positive RDT may not require confirmation by molecular testing. There is therefore the need to develop RDTs in-country that will take into consideration the unique environmental factors, interactions with other infectious agents, and strains of the virus circulating locally. This may enhance the precision of rapid and accurate diagnosis of COVID-19 in Nigeria.
dc.description.departmentSchool of Health Systems and Public Health (SHSPH)
dc.description.librarianam2025
dc.description.sdgSDG-03: Good health and well-being
dc.description.sponsorshipThe Government of Nigeria through the Nigeria Centre for Disease Control and Prevention (NCDC), Nigerian Institute of Medical Research (NIMR), the Tertiary Education Trust Fund (TETfund), and the World Bank through the Regional Disease Surveillance Systems Enhancement (REDISSE) project.
dc.description.urihttps://journals.plos.org/globalpublichealth/
dc.identifier.citationOmonkhua, A.A., Faneye, A., Akinwande, K.S., Evaezi, O., Shehu, N.Y., Onayade, A., et al. (2024) Performance evaluation of SARS-CoV-2 rapid diagnostic tests in Nigeria: A cross-sectional study. PLOS Global Public Health 4(7): e0003371. https://doi.org/10.1371/journal.pgph.0003371.
dc.identifier.issn2767-3375 (online)
dc.identifier.other10.1371/journal.pgph.0003371
dc.identifier.urihttp://hdl.handle.net/2263/102753
dc.language.isoen
dc.publisherPublic Library of Science
dc.rights© 2024 Omonkhua et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
dc.subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
dc.subjectDiagnostic tests
dc.subjectNigeria
dc.subjectCOVID-19 pandemic
dc.subjectCoronavirus disease 2019 (COVID-19)
dc.subjectReverse transcription polymerase chain reaction (RT-PCR)
dc.subjectRapid diagnostic test (RDT)
dc.titlePerformance evaluation of SARS-CoV-2 rapid diagnostic tests in Nigeria : a cross-sectional study
dc.typeArticle

Files

Original bundle

Now showing 1 - 5 of 5
Loading...
Thumbnail Image
Name:
Omonkhua_Performance_2024.pdf
Size:
863.95 KB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
Omonkhua_PerformanceFileS1_2024.docx
Size:
20.5 KB
Format:
Microsoft Word XML
Description:
File S1
Loading...
Thumbnail Image
Name:
Omonkhua_PerformanceTableS1_2024.docx
Size:
112.1 KB
Format:
Microsoft Word XML
Description:
Table S1
Loading...
Thumbnail Image
Name:
Omonkhua_PerformanceChecklistS1_2024.docx
Size:
35.93 KB
Format:
Microsoft Word XML
Description:
Checklist S1
Loading...
Thumbnail Image
Name:
Omonkhua_PerformanceChecklistS2_2024.docx
Size:
42.21 KB
Format:
Microsoft Word XML
Description:
Checklist S2

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: